Novanta CEO Sells Shares: What It Means for NOVT Stock

On February 2, 2026, Novanta CEO Matthijs Glastra sold 6,500 shares of the company in open-market transactions. The sale was executed under a Rule 10b5-1 trading plan, which he adopted in September 2025. These plans allow corporate insiders to schedule stock sales in advance to avoid accusations of trading on non-public information.

The transaction was valued at approximately $878,458 based on a weighted average price of $135.15 per share. Following the sale, the CEO's direct ownership stake decreased by about 9%, leaving him with 64,867 directly-held shares worth roughly $8.7 million, plus an additional 54,382 shares held indirectly through a trust.

This sale is consistent with the CEO's recent trading pattern. Over the past fifteen months, his direct holdings have declined by 56.54% through regular sales. The 6,500-share transaction size is in line with his median sale size of approximately 6,339 shares since November 2024.

The selling activity reflects a diminishing pool of available shares rather than a change in selling behavior. Importantly, the transaction did not affect the CEO's indirect holdings or involve any derivative instruments, suggesting it was a straightforward liquidity event.

The timing of this sale coincides with Novanta's strong stock performance in 2026, with shares up approximately 23% year-to-date through late February. This rally has pushed the stock to valuation levels not seen in the past year, with a price-to-earnings ratio approaching 100.

Novanta's business fundamentals appear solid. The company reported third-quarter revenue of $247.8 million, up from $244.4 million a year earlier. More importantly, bookings grew 17% year-over-year, indicating strong future demand for its photonics, vision, and precision motion components used in medical and industrial applications.

The combination of strong operational performance and rich valuation creates a mixed picture for investors. While the CEO's sale was pre-planned and therefore not necessarily a bearish signal, the stock's elevated valuation suggests limited near-term upside potential.

For current shareholders, the key consideration is whether Novanta can grow into its current valuation. The 17% bookings growth provides some confidence, but execution risks remain in converting those bookings into sustained revenue and profit growth.

Investors should monitor whether this insider selling pattern continues among other executives and directors, which could indicate broader concerns about the stock's valuation or business prospects.